Slate Pharmaceuticals Selects OpenClinica Enterprise

OpenClinica announced today that Slate Pharmaceuticals has selected the OpenClinica Enterprise clinical trials software solution to power the development of innovative men’s and women’s health products.

Durham, NC-based Slate is a specialty pharmaceutical company focused on the commercialization of health products for maturing men and women. Slate’s current main focus is Testopel®,   a subcutaneous pellet delivery of testosterone replacement therapy for men suffering from low testosterone levels, more commonly referred to as Low T.

“Even though we are a small, specialty pharmaceutical company, it is important for us to have a robust and regulatory compliant means for conducting clinical research,” said Christine Burns, Slate’s Clinical Manager. “OpenClinica’s flexible, open technology enables us to undertake higher quality and more efficient clinical trials that can help define important new treatments in the area of men’s health.”

OpenClinica Enterprise is commercial open source software for clinical trial electronic data capture (EDC) and clinical data management (CDM). It enhances the quality and speed of clinical research by leveraging open standards in an easy-to-use, hassle-free solution.

“We are enthusiastic about bringing OpenClinica Enterprise to enhance Slate’s innovative work contributing to improvement in men’s health,” said Cal Collins, OpenClinica’s CEO. “Increased transparency into clinical trial progress and more rapid access to higher quality clinical trial data are just a few of the numerous benefits we will work with Slate to realize.“